{"name":"Acura Pharmaceuticals Inc.","slug":"acura-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Acurox 7.5/30","genericName":"Acurox 7.5/30","slug":"acurox-7-5-30","indication":"Moderate to severe acute pain","status":"phase_3"}]}],"pipeline":[{"name":"Acurox 7.5/30","genericName":"Acurox 7.5/30","slug":"acurox-7-5-30","phase":"phase_3","mechanism":"Acurox 7.5/30 is a combination of oxycodone and acetaminophen designed with abuse-deterrent technology to reduce the risk of misuse and overdose.","indications":["Moderate to severe acute pain"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQbWNmeFVJaTRrNFU2aFByMS05UEtGa29yX2VVdmtvVng2NTB4c2lGOXoyem9aSXRwbjNFVGJUaTVKMllfOTViQWM5emsyZlJ1NG56eFRJUTFnNnQ5U2FxM3h4TnhvcEg1SDZnRWt1cXh2NWJMSGwzZDFBZGo1b1lxNmZLN2hwbGMzMnRyYVV5eGFwNThJczk1b0E0R04wLTExdmJHcGZGRkFuZw?oc=5","date":"2026-03-27","type":"pipeline","source":"Stock Titan","summary":"Acura Pharmaceuticals (NASDAQ: ACUR) cites liquidity, misses 2025 Form 10-K filing - Stock Titan","headline":"Acura Pharmaceuticals (NASDAQ: ACUR) cites liquidity, misses 2025 Form 10-K filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQZDhiVnJCWnUydFZTNFBrRm9jYmotdFpIREE4V0ZhNHMtOV85MDhCTjh6MzViRnFNOS0td0pXNVY5R21XRzZIdFJNNW9ZcC1tV25GdkZWdm9ZcjNvWE5zQ3FYMmtaTkphaHNEZWgtVmoyX2ZhZEE2WkJTUzhLWGlMbnByY0JUYWZGaXdydFIyTjFEZE1tUUhIbmpLdG5VZ1JrbHd2bXlLOWE2M3R4?oc=5","date":"2026-03-27","type":"pipeline","source":"TipRanks","summary":"Acura Pharmaceuticals Delays Multiple Annual SEC Filings - TipRanks","headline":"Acura Pharmaceuticals Delays Multiple Annual SEC Filings","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-12","type":"pipeline","source":"GlobeNewswire","summary":"Pharmaceutical and Biotechnology Royalty Rates Agreements - GlobeNewswire","headline":"Pharmaceutical and Biotechnology Royalty Rates Agreements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPeTdzZjhVNFJmVDV1TktWRWtQNWtxT2V4RjIyN01MNmFNa3ZZLUJCdGZIR2FkMVJIeVpmdUNodlp2dFluQ1F1YlY4X0E3b2JmZTQ1RkR6a2dEYkhyTEJhRF95MEVFMHBjNzVMaVlGeG4xRUJ6QVcwbkkwbzFMVmJSRndRNE9vb01TVjBrYnRYUGFUSjVkOWxWRjlSUFI1a1dZVUpRQUpWXzdDSzZpNXZNX1MxQQ?oc=5","date":"2026-03-10","type":"pipeline","source":"TipRanks","summary":"Acura Pharmaceuticals Secures New Loans Amid Liquidity Strain - TipRanks","headline":"Acura Pharmaceuticals Secures New Loans Amid Liquidity Strain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wJBVV95cUxPWnZsQTktLS16RWxLX2t5S3l5WnF4b1VBUEVENkE3Y1RKenJsblFxOTJWcFJLYnl6V05ZRl94VlFRZU05QkxLcUM5VW9uWVNKeU5GTzZvWW1ZY1hFRzZYYVFCV1hRRkNXbC05SnBRNmlBa0VvZkhEeU92SF93X1ltbHFfMGtCVDNZN1ZGTFVCd0o4ek1JNlBINnFXaEVxQXhVd1BWd0VUamtsYkxoMUptT2l2MFRTNC1KeVdEZ3RkdXlmQ1FhRkFObVlmYU40R3BMLU1SMC1rQjV1NXRsMmdyVGlrUWM4TzVQYl9aWFpmT29GRFNTRDFmV3lxS01iV2RRdk0wMERhMEFaTUNORzd4MURjR3RmLTFySGgxRGQ4d1J1UnVQRXF4T25tMmszcUNELWRMRDhxc3VvTUVjZ0Q1YzRISl9sMkFIcWYyUExRU1ctZFpCSXJUVXFMYnNXRTA?oc=5","date":"2025-11-12","type":"deal","source":"businesswire.com","summary":"Royalty Rates in Pharmaceutical and Biotechnology Deals 2010-2025 - Uncover 1,700+ Partnering Deals and Benchmark Deal Structures with Actual Licensing Agreements - ResearchAndMarkets.com - businesswi","headline":"Royalty Rates in Pharmaceutical and Biotechnology Deals 2010-2025 - Uncover 1,700+ Partnering Deals and Benchmark Deal S","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNLVFDbXJxWVROaWlycndqLTMzbGZmb1RDQ0pmMlNfNDNnRFpTb0Q4bjJaZTVVNVh5X1ZmRGRXdUlYZXhiNFZEMXMwRHhKSXZxUmdIXzlOb1JWREhGM1pkRUpOYmVtXzZUV1dTVjZaOVVEdmFMMm9ZYk5zcVp1MUdHbDY2THY1SkVnd3c3cEN3WU1Xd1hLVFdHSllSYjI?oc=5","date":"2025-06-09","type":"pipeline","source":"Pharmacy Times","summary":"Because Ned Said: New Technology Helps Prevent Opioid Overdose - Pharmacy Times","headline":"Because Ned Said: New Technology Helps Prevent Opioid Overdose","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNUXFUWElQRVdHY2FCd01HMlpJRXZzc1pmZE1idGdoeUM5cU1laC1lN2xwX2o4UEVWc3Rpd0FELUtuZjFCMXRVU2lHZlp4Qzg0X2hId0F6UlBfQk1rUDlZbE02UXdjd0NvWEFna2wxTkduNGxMU2xxY2hpTGdXNmM1eHJJQTl2d1hpQjRRTnotSmhVUEw3MFloaE5IOUZpZkhxV3hFOWhJcUl3Y2syZ21PMlp3SmhxbmF1a1hJSkg4TE9vQ2JW?oc=5","date":"2025-04-23","type":"pipeline","source":"Investing.com","summary":"Acura Pharmaceuticals secures additional funding amid financial strain - Investing.com","headline":"Acura Pharmaceuticals secures additional funding amid financial strain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE0zdUd2VndId0pHRTVPSC1EMWtQdlJHTUdqMndSQzRCYWt4dDdNdkNVbVR1M3EyeHlnanU4eG5CQXR1QkUxWjBJc2VuMFpMcWVUbXhXLWhfQjBmZzQ?oc=5","date":"2017-11-15","type":"pipeline","source":"MarketBeat","summary":"Acura Pharmaceuticals (ACUR) Stock Price, News & Analysis - MarketBeat","headline":"Acura Pharmaceuticals (ACUR) Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE9telg2R0hMZGphcThfUnBxOHlNb3NIbGt0RzBsYW9ZNnlHMGxadjZ3cENGWG5BUWtPdkZtNVdwTmFPVHNrMnp1Vkt2OV9pUlFGQXc?oc=5","date":"2017-05-19","type":"pipeline","source":"Yahoo Finance UK","summary":"Acura Pharmaceuticals, Inc. (ACUR) stock price, news, quote and history - Yahoo Finance UK","headline":"Acura Pharmaceuticals, Inc. (ACUR) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQU1N4a3Z1RklqaUx3dEVrdjhLUDdpNWVNa3RUN1FOY1pjVjdtRWViR1VTUXVLYVd4aXpaUXV4NWVocDFlanlqVUdkcF9CQmJZN19YaXYydzJCbzBad05aWDkwRF9oWTdRS0hqb2pMWWhhMmFVclNoWXVWZnVYMF9VLXAxbHhZX3lpZk5DSGhlbUZ5dVZZaFg0ODR3eXAydndqTFVMZ3Axa1kzb2N5VWJNNjVtM2RQOExrbnc?oc=5","date":"2016-05-23","type":"patent","source":"prnewswire.com","summary":"Purdue Pharma Announces Patent Agreement with Egalet and Acura - prnewswire.com","headline":"Purdue Pharma Announces Patent Agreement with Egalet and Acura","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNZzhBVzVQRTlLQmdHcW43VUNwT2FoOHRsOHNHcDdxczdmaGRVWmc5ZlVDY3MwWGNwcXE5MWxoakl6UUFrRXIzZnFkNjhlQ09LRlZObktEbmtHc2hlLXNvOXFnclc3R05felFxZmdNRTBCRG94MUFycF9JMG9CeVRHUV8wenF3UW5GbmxtTEZGX3FDbGhvVm5lVkx3RjY3cFNtNjQxOA?oc=5","date":"2014-05-23","type":"patent","source":"BioPharma Dive","summary":"Acura Pharmaceuticals settles patent litigation with Sandoz - BioPharma Dive","headline":"Acura Pharmaceuticals settles patent litigation with Sandoz","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQTTJvUmpaUjZzeU1LdzJ1LUtNUEQwa3Rncm5ocTNVR2k0dzFldlNXUU5VVE5NQ2JkVnV6YXFMT3dZQ0ZXNGM3NW1oN0c2aFBPbURfUDBaQUtzNlliU3loNGJ5eHN5azNnaUtlckpKOEFUOFNRNnBBYXQ4VGJucnVMX0tsRDBmekl2bUhZaXRpTDJMZTI0ZG9CekFIWExtWElv?oc=5","date":"2009-03-03","type":"pipeline","source":"RTTNews","summary":"Acura Pharma gets priority review for Acurox tablets - update - RTTNews","headline":"Acura Pharma gets priority review for Acurox tablets - update","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}